NEL ASA: Awared electrolyser contract by Marsa in Turkey

( Oslo, 9 September 2016) New NEL Hydrogen AS, a NEL ASA subsidiary, has been awarded a contract by Marsa, a world-leading producer of margarine and liquid oils, for the delivery of a hydrogen electrolyser plant with supplementary equipment. The agreement has a total value of around EUR 1 million.

“Industrial customers are the most demanding, as they require the highest efficiency combined with outstanding reliability, robustness and low operating costs. It is encouraging to see that demanding industrial customers like Marsa continue to order our equipment. This confirms that NEL elctrolysers remain the preferred solution”, says Lars Markus Solheim, SVP Nel Hydrogen Electrolyser.

The project represents an extention of the existing hydrogen production capacity operated by Marsa and the Ülker Group.

For additional information, please contact:

Jon André Løkke, CEO, +47 90 74 49 49

Bjørn Simonsen, market development and public relations, + 47 97 17 98 21

About NEL

Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store and distribute hydrogen from renewable energy. We serve industries, energy and gas companies with leading hydrogen technology. Since its foundation in 1927, Nel has a proud history of development and continual improvement of hydrogen plants. Our hydrogen solutions cover the entire value chain from hydrogen production technologies to manufacturing of hydrogen fueling stations, providing all fuel cell electric vehicles with the same fast fueling and long range as conventional vehicles today.

About Us

NEL ASA is a leading global supplier of hydrogen technology for industrial / energy purposes, and has made over 500 deliveries in more than 50 countries. The company's main products are hydrogen production plants based on water electrolysis, complete hydrogen stations for transport and renewable energy storage solutions. The company has its roots from the hydrogen activities of Norsk Hydro, which dates back to 1927. The company also has a number of patents related to tests for early detection and diagnosis of diseases.